Avidity Partners Management LP Nurix Therapeutics, Inc. Transaction History
Avidity Partners Management LP
- $370 Million
- Q2 2025
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
174Shares Held
79.4MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$61.9 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$55.1 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$40.5 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$35.9 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$35.2 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $428M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...